Hi! My name is Floris van Dalen, I am from a small town in the south of South Holland and just started my second year as a PhD candidate in the group of Martijn Verdoes at Tumor Immunology under the theme Cancer development and immune defense.
When you were a kid what did you want to be when you grew up? Can you tell us something about your child years.
When I was young, I was always running around and did real boy stuff, like building tents and making catapults. I always loved nature but I didn’t really have an idea of doing a PhD in chemical immunology just jet. The first time I thought about career choices was during an orientation course at school where I interviewed my chemistry teacher. I was fascinated by the experiments we were doing in class like making soap and galvanising test tubes.
What was your previous academic training, where did you study and why that study?
I have studied chemistry at the University of Leiden and during my masters I specialized in the area of chemical biology. At the time I just really liked organic chemistry and wanted to understand how molecular forces shape the macroscopic world we experience every day. Later, I realised that these same dynamics also describe the driving forces of biological processes and I became especially interested in chemical immunology. I think delineating the way our immune system works at the molecular level will help us understand multi-faceted illnesses as cancers, dementia and cardiovascular diseases.
The RIMLS motto is: ‘Today’s molecules for tomorrow’s medicine’. What does this mean for you?
For me it shows the strong connection of the UMC in medical and translational research. Sometimes you lose yourself in the practical aspects of your research (which is good) and the motto serves as a great reminder that in the end we would like to help patients get better.
Who is your great example as scientists? And please give a motivation why.
Gijs. Gijsbert van der Marel was my professor in Organic Chemistry and he is the most passionate and colourful researcher that I have met. His classes were always captivating and he really motivated me as a student. My time in his research group showed me how important teamwork is in science and how an inviting and open atmosphere catalyses discussions and the development of new ideas.
Which research discovery that you have made has made you most proud?
I work on the development of a novel targeted small molecule approach to modify the tumor microenvironment. Last month, we were able to perform a proof‑of‑principle experiment in RAW macrophages to test the targeted delivery of monomethyl auristatin E, a cytostatic drug. Seeing my own product work in early biological experiments was really motivating. We are currently expanding this project to incorporate immunomodulatory drugs that reactivate tumour-associated macrophages to improve immunotherapy.
Given unlimited finance what experiment would you perform?
There are lot of exciting and promising immunotherapies in the treatment of cancer, such as checkpoint inhibition or dendritic cell vaccination. Immunotherapy has shown great promise in curing cancer patients for long periods of time. However, standard practise right now doesn’t directly combat the cause of tumour development. Hence, if given infinite amount of money I would like to look further into the influence of our immune system on the development of malignant tumours and I hope this immunotherapy research would ultimately lead to the development of (more available) curative treatments for cancer.
What does your working area (desk, office) look like and what does it say about you (or your research)?
Organised chaos. I think it symbolises the chaos that is nature and how I attempt to organise it.
Nominate a colleague to be in the spotlight and what would you like to ask him or her?
Felix Fennemann, I would like to ask him how he makes his amazing presentations.
What type of person are you, quick insights:a) Mac or PC? : Personal Computer
b) Theater or cinema? : Concerts
c) Dine out or dine in? : Dine in (I love cooking)
d) Ferrari or Fiat? : Toyota
e) Shopaholic or chocoholic? : Neither really. (I really love good food though.)
f) Culture or Nature : I love both
Related news items
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more
Summer greetings from René Bindels16 July 2020
In this last newsletter before most colleagues enjoy their well-deserved summer break, I would like to briefly summarize the first part of 2020 and look ahead to the many activities that will take place in the coming months of this unprecedented year.read more
Registration for Social Dutch course for researchers is open now14 July 2020
In October, a new course Social Dutch will start at Radboud In’to Languages. The course is very popular and we are happy to inform you that registrations for Social Dutch have been opened now!read more